Context Therapeutics (CNTX) Common Equity (2020 - 2026)
Context Therapeutics (CNTX) posted Common Equity of $52.2 million for Q1 2026, down 13.68% sequentially from $60.5 million in Q4 2025, and down 42.62% YoY from $91.0 million in Q1 2025.
Context Therapeutics (CNTX) Common Equity (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Common Equity for 7 years, with the latest figure at $52.2 million in Q1 2026.
- Quarterly Common Equity fell 42.62% year-over-year to $52.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.2 million (down 42.62% YoY) and the FY2025 annual result came in at $60.5 million, down 36.52% from the prior year.
- Common Equity retreated to $52.2 million in Q1 2026 per CNTX's latest filing, from $60.5 million in the prior quarter.
- Over five years, Common Equity peaked at $101.1 million in Q2 2024 and troughed at $8.4 million in Q1 2024.
- A 5-year average of $52.4 million and a median of $45.4 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 70.61% in 2024, then soared 977.58% in 2025.
- Over 5 years, Common Equity stood at $34.8 million in 2022, then plunged by 65.85% to $11.9 million in 2023, then jumped by 702.51% to $95.3 million in 2024, then slumped by 36.52% to $60.5 million in 2025, then slipped by 13.68% to $52.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $52.2 million, $60.5 million, and $73.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 38.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.17 Mn |
| Mar 31, 2026 | 52.20 Mn |
| Dec 31, 2025 | 60.47 Mn |
| Sep 30, 2025 | 73.17 Mn |
| Jun 30, 2025 | 82.54 Mn |
| Mar 31, 2025 | 90.98 Mn |
| Dec 31, 2024 | 95.27 Mn |
| Sep 30, 2024 | 83.86 Mn |
| Jun 30, 2024 | 101.10 Mn |
| Mar 31, 2024 | 8.44 Mn |
| Dec 31, 2023 | 11.87 Mn |
| Sep 30, 2023 | 18.38 Mn |
| Jun 30, 2023 | 24.00 Mn |
| Mar 31, 2023 | 28.73 Mn |
| Dec 31, 2022 | 34.76 Mn |
| Sep 30, 2022 | 38.07 Mn |
| Jun 30, 2022 | 41.65 Mn |
| Mar 31, 2022 | 45.39 Mn |
| Dec 31, 2021 | 48.27 Mn |
| Sep 30, 2021 | -23.21 Mn |